About Signal Pharmaceuticals
Signal Pharmaceuticals is a company based in San Diego (United States) founded in 1993 was acquired by Celgene in June 2000. Signal Pharmaceuticals has raised $12 million across 2 funding rounds from investors including New York Life Insurance, Celgene and Robertson Stephens Partners. Signal Pharmaceuticals operates in a competitive market with competitors including eGenesis, Beam Therapeutics, Korro Bio, Scribe Therapeutics and Tessera Therapeutics, among others.
- Headquarter San Diego, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$12 M (USD)
in 2 rounds
-
Latest Funding Round
$12 M (USD), Series E
Sep 17, 1997
-
Investors
New York Life Insurance
& 5 more
-
Employee Count
Not available
-
Acquired by
Celgene
(Jun 30, 2000)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Signal Pharmaceuticals
Signal Pharmaceuticals has successfully raised a total of $12M across 2 strategic funding rounds. The most recent funding activity was a Series E round of $12 million completed in September 1997. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Signal Pharmaceuticals
Signal Pharmaceuticals has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include New York Life Insurance, Celgene and Robertson Stephens Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on tech sectors
|
Locked | Locked | Locked | |
|
Global financial advisory services are provided by the firm.
|
Locked | Locked | Locked | |
|
Mutual life insurance and asset management services are provided.
|
Locked | Locked | Locked |
Investor details for Signal Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Signal Pharmaceuticals
Investment portfolio details for Signal Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Signal Pharmaceuticals
Detailed financials for Signal Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Signal Pharmaceuticals Comparisons
Peer comparison for Signal Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Signal Pharmaceuticals
Signal Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as eGenesis, Beam Therapeutics, Korro Bio, Scribe Therapeutics and Tessera Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Gene transplantation platform for humanizing pig cells is developed.
|
|
| Locked | Locked | Locked |
Developer of gene therapy using CRISPR base editing to treat diseases
|
|
| Locked | Locked | Locked |
RNA-editing technologies are provided for precision medicine applications.
|
|
| Locked | Locked | Locked |
A CRISPR-based gene-editing platform is developed for therapeutic applications.
|
|
| Locked | Locked | Locked |
New genome engineering technology is provided for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for infectious disease and inflammatory indications
|
Detailed competitors of Signal Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Signal Pharmaceuticals
Complete news archive for Signal Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Signal Pharmaceuticals
Signal Pharmaceuticals was founded in 1993.
Signal Pharmaceuticals is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Signal Pharmaceuticals is a funded company, having raised a total of $12M across 2 funding rounds to date.
Signal Pharmaceuticals was founded in 1993 in San Diego, United States, within the biotechnology sector. Research and development efforts are directed toward small molecule drugs that modulate disease-related genes. Advanced cellular, molecular, and genomic technologies are utilized to map gene-regulating pathways and identify proprietary targets for gene activation or deactivation. Partnerships with pharmaceutical companies are formed to advance drug discovery for disease-associated genes.
Signal Pharmaceuticals's top competitors include eGenesis, Tessera Therapeutics and Korro Bio.
Signal Pharmaceuticals has 6 investors. Key investors include New York Life Insurance, Celgene, Robertson Stephens Partners, Ares Serono, and Lehman Brothers.